Apellis reports discontinuation of MERIDIAN study
Pharmaceutical company Apellis has announced the discontinuation of the open-label phase of…
![Stay in [u]touch[/u]](/static/paper-plane.svg)
Recording of virtual meeting – Adherence and retention in ALS clinical trials
On March 22, 2023, TRICALS organised its first virtual meeting: ‘Adherence and retention…
COURAGE-ALS trial discontinued due to disappointing results
The company Cytokinetics has announced early termination of the COURAGE-ALS study. An…
TRICALS consensus statement on Tofersen
OPINION: The consensus view of TRICALS neurologists is that Tofersen shows clear…
The ATLAS study – A clinical trial for people who want to contribute to SOD1-ALS research
Biogen is conducting a clinical trial to evaluate the efficacy and safety…
Food and Drug Administration (FDA) approves AMX0035 (Amylyx) for the American market
During a meeting of the FDA’S Peripheral and Central Nervous System Drugs…
Measuring treatment effects based on patient preference
To evaluate the effect of an investigational drug in ALS clinical trials,…
TRICALS Enrols First Participants in Phase 3 MAGNET platform trial for ALS
TRICALS (the Treatment Research Initiative to Cure ALS), in collaboration with ALS…
USA: new law promises $100 million for ALS research
A new law has been passed in the United States to give…
Congratulations to our TRICALS colleagues as UK Government invests £50 million to find a cure for ALS
The UK government has recently announced that £50 million will be invested…